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Efficacy and safety of growth hormone treatment in short children with
renal allografts: Three year experience. The majority of children with
renal allografts have diminished growth and reduced final height.
Impaired allograft function and glucocorticoid treatment are the main
contributing factors. Since recombinant human growth hormone
(rhGH) treatment was able to counteract the growth depressing effects
of glucocorticoids in experimental uremia, an open-labeled prospective
study in 17 short children with renal allografts was designed to
investigate the efficacy of rhGH therapy (30 IU/m2/week) with special
emphasis on the safety regarding graft function and carbohydrate
metabolism. Height velocity in prepubertal children (N = 10) increased
from baseline median 2.2 cm/year to 7.9 cm/year after one year (P <
0.01), 7.2 cm/year after two years (P < 0.01), and 5.5 cm/year (P < 0.05)
after three years of rhGH therapy. This resulted in a normalization of
height in three out of seven patients after two years and in three out of
five after three years of therapy. Growth stimulation in pubertal
children was less consistent. Bone maturation paralleled chronological
age. The effect of rhGH treatment on longitudinal growth may be
partially attributable to the improved ratio between the serum concen-
tration of the insulin-like growth factor (IGF)-I and its major binding
protein (BP) IGFBP-3 leading to a normal IGF bioactivity. The inci-
dence of acute rejection crises in the study group (corrected for time
after grafting) did not differ from that of untreated retrospective
"controls" (0.10 vs. 0.12 episodes per patient and year). No systematic
effect of rhGH on glomerular filtration rate assessed by repeated inulin
and creatinine clearances was noted. The major metabolic effect of
rhGH was a continuous increase in fasting and stimulated insulin serum
levels up to three years, whereas glucose tolerance did not change with
time. It is concluded that rhGH markedly improves growth of prepu-
bertal children with renal allografts without obvious serious side effects
within the observation period of three years. Therapy with rhGH may
become a new treatment modality in short slowly growing children after
renal transplantation.
pathophysiological mechanism of growth failure in transplanted
children is multifactorial, the main contributing factors are graft
function and glucocorticoid treatment for immunosuppression
[2j. Glucocorticoids in pharmacological doses may suppress
growth hormone (GH) secretion by increasing the hypothalamic
somatostatin release [3]. This inhibitory eflct on spontaneous
GH secretion appears to be dose dependent [41. Glucocorti-
coids interfere also directly with skeletal growth by inhibiting
bone formation and collagen synthesis [5]. In addition, a
pronounced catabolic action of glucocorticoids, promoting the
loss of tissue mass and negative nitrogen balance is noted [61.
Recently, we could demonstrate in animal experiments that
recombinant human (rh) GH is able to counterbalance the
growth depressing effects of glucocorticosteroids in animals
with normal and reduced renal function [7]. These studies were
confirmed by short-term studies in children with renal allografts
[8—10]. The present study documents for the first time a growth
promoting effect of rhGH over a period of up to three years. In
addition, we especially focussed on the effect of rhGH on graft
function using single injection inulin clearances (C1) and on
glucose metabolism. Because deterioration of graft function and
induction of allograft rejection crises are a matter of concern for
rhGH therapy, the glomerular filtration rate (GFR) and the
number of rejection crises were compared to that of retrospec-
tive "control" allograft recipients without rhGH treatment,
who were observed during the same time period.
Methods
Patient inclusion criteria
Growth retardation in children after renal transplantation
remains an unsolved clinical problem. Catch-up growth is not
uniformly obtained and appears to be restricted to patients
under the age of seven on low-dose glucocorticoids [1]. The
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Seventeen patients (3 girls, 14 boys) were selected from five
German centers of Pediatric Nephrology on the basis of the
following criteria: (1) Growth retardation defined as a height
standard deviation score (SDS) for chronological age (CA) of
—2.0 and a height velocity SDS-CA of using the first
Zurich longitudinal growth study as a reference [11]; (2) At
least three separate height measurements of the previous year
performed at the clinic of the responsible investigator; (3) CA
>3 years; (4) Stable renal graft function with a glomerular
filtration rate (GFR) >20 ml/min/1.73 m2, at least 18 months
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Table 1. Patient data at start of GH therapy
Peak GH plasma
GH peak level during
Age Bone age Pubic Time since amplitude during stimulationPatient hair transplantation MP dose GH night profile with arginine
no. Gender years stage Primary renal disease years mg/m2/day ng/ml ng/ml
1 m 7.8 3.1 PHi Multicystic dysplasia 2.8 5.la 13.4 14.8
2 m 8.1 3.3 PH1 Obstructive uropathy 1.5 9.1 11.6 25.0
3 m 8.1 3.9 PHi Renal hypoplasia 5.1 3.6 9.4 16.1
4 m 8.1 4.8 PH1 Multicystic dysplasia 1.5 6.1 26.4 12.7
5 m 10.2 6.2 PHi Alport syndrome 1.8 6.1 11.1 20.0
6 m 10.6 6.5 PH1 Reflux nephropathy 2.3 3.7 15.8 22.5
7 m 12.5 6.5 PH1 Infantile nephropathic 1.5 4.6 63.3 53.8
cystinosis
8 f 13.2 9.5 PH1 Hemolytic-uremic 10.7 6.1 5.5 8.1
syndrome
9 m 13.8 12.0 PH3 Infantile nephropathic 1.8 8.3 69.9 64.9
cystinosis
10 m 13.9 9.8 PH2 Focal segmental 4.8 12.9 10.1 13.1
sclerosis
11 m 14.6 10.3 PH2 Juvenile cystinosis 2.8 3.1 41.1 13.9
12 m 15.2 10.1 PH3 Obstructive uropathy 4.1 6.1 10.3 12.5
13 f 17.3 12.8 PH3 Renal hypoplasia 5.7 9.4 — —
14 m 17.9 14.8 PHI Obstructive uropathy 6.6 5.6 — —
15 f 18.0 10.3 PHi Infantile nephropathic 11.0 5.4 14.8 7.2
cystinosis
Median 13.2 9.5 2.8 6.1 13.4 14.8
(range) (7.8—18.0) (3.1—14.8) (1.5—11.0) (3.1—12.9) (5.5—69.9) (7.2—64.9)
MP denotes methyiprednisolone.
a Alternate day therapy
Table 2. Comparison of patient characteristics and growth in rhGH treated subjects and "controls"
Immuno- Height SDS/year
Patient Age suppressive MP doses Baseline Before 1st year of 2nd year of 3rd year of
number years Gender regimen mg/m2/day height SDS treatment treatment treatment treatment
Patients with 15 13 3 f/12 m 6 CsA/MP 61d —0.1 o.sa o.5a 0.1c
rhGH (8—18) 9 CsA/AZA/MP (3.1 to 12.9) (—7.5 to —2.0) (—1.0 to 1.2) (0 to 1.0) (—0.3 to 2.5) (—0.1 to 0.9)
treatment N = 11 N = 9
"Controls" 27 15 12 f/15 m 17 CsAIMP 4.0 —2.5 —0.1 0 0 —0.1
(5—18) 10 CsA/AzaJMP (2.6 to 15.1) (—5.1 to 0) (—1.2 to 1.0) (—1.4 to 2.5) (—0.8 to 0.8) (—0.7 to 0.6)
N=21 N=11
CsA denotes cyclosporin A; MP, methyiprednisolone, and AZA, azathioprine.
ap< "p <0.05, 'P = 0.09 vs. "controls"
Alternate day therapy d in 2, in 4 patients
should have passed since transplantation. (5) In pubertal chil-
dren, no more than one year should have passed since the first
sign of puberty. (6) No evidence of hypothyroidism, hypopara-
thyroidism, diabetes insipidus, Addison's disease, malignancy,
major cardiopulmonary disease, or nephrotic syndrome (de-
fined as >40 mg urinary protein/rn2 body surface area/hr and
serum albumin <25 g/liter). (7) Previous anabolic or sex steroid
treatment.
Written informed consent was obtained from parents.
Patient data
Details of 15 patients treated over at least six months are
shown in Table 1. One patient stopped treatment after six
weeks because of rising serum creatinine levels, and one patient
after three weeks because of sudden deterioration of hyperten-
sion.
To analyze the decline of GFR and the incidence of acute
rejection crises, we compared these patients with a retrospec-
tive "control" group of 27 patients not treated by GH, who had
received their allografts within the same time period as the
rhGH treated patients. "Controls" had similar age and immu-
nosuppressive drugs, and the methylprednisolone dose was
slightly higher in the rhGH treated group (Table 2). The analysis
in the "controls" (that is, the period of comparison with the
rhGH treated patients) started two years after transplantation
with a median follow-up of two (1 to 3) years.
Treatment regimens
The dose of rhGH was 30 lU/rn2 body surface area/week
(Genotropin, Kabi Pharmacia AB, Sweden), given as a daily
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evening subcutaneous injection. The study protocol was ap-
proved by the Ethical Committee of the University of Heidel-
berg and by the independent Freiburger Ethikkommission.
Physical assessments
The patients had a physical examination before treatment, at
six weeks, and at 3, 6, 9, and 12 months during the first
treatment year and at six-monthly intervals in the following
years. Height was taken as a mean of three measurements with
a Holtain stadiometer (Holtain Ltd., Crymych, Dyfed, UK).
Weight was measured with electronic scales. For calculations
of height SDS and height velocity SDS, the standards from the
Zurich longitudinal growth study [11] were used. Triceps skin-
fold (TSF) thickness was measured with a Holtain skinfold
caliper and mid-arm circumference with a flexible non-stretched
tape [12]. Mid-arm muscle circumference (MAMC) was calcu-
lated as follows: MAMC (in cm) MAC (in cm) minus (0.314)
TSF thickness (in mm). Bone age was assessed at yearly
intervals by the same independent observer (B.S.), using the
TW2 method (TW2-RUS) [13]. At each visit to the clinic, the
stage of puberty was assessed by the method of Tanner [14].
Systolic and diastolic blood pressure were measured at each
visit.
Laboratory studies
All investigations were performed in fasting patients at inter-
vals of three or six months. At each visit to the clinic, blood
samples were taken for measurements of hemoglobin concen-
tration, white cell and platelet counts, serum electrolytes,
phosphate, liver function tests, creatinine, urea, alkaline phos-
phatase, fasting triglyceride, and cholesterol concentration.
Glycosylated hemoglobin concentrations were measured cen-
trally by the microcolumn technique as described by Friedmann
and Humbert [15]. Intact parathyroid hormone (PTH) in plasma
was determined by a two side radioimmunoassay [16]. A
morning urine sample was used for measuring the calcium:
creatinine ratio. Serum concentrations of thyrotrophin (TSH),
triiodothyronine and thyroxine were measured every six
months during the first year of treatment and thereafter at the
end of each treatment year.
Single injection C1 for estimation of GFR were performed
regularly in 10 children during the first treatment year: 0.3 mi/kg
body weight inulin (Inutest, Laevosan-Gesellschaft, Linz, Aus-
tria) were injected i.v., and serum samples collected before
injection, after 30, 60, 120 minutes and every 60 minutes
thereafter up to five hours. Inulin was determined enzymati-
cally according to Kuehnle, Dahl and Schmidt [17]; the clear-
ance was evaluated by a one-pool model according to Newman,
Bordley and Winternitz [18] using only the non-exponential part
of the plasma concentration curve for calculation. In addition,
GFR was estimated in all children by creatinine clearance (Car),
according to the method of Schwartz, Haycock and Edelmann
[19].
Glucose regulation was assessed by an oral glucose tolerance
test (OGTT) (1.75 g glucose/kg body wt; maximum 75 g) after an
overnight fast before treatment and thereafter at yearly inter-
vals. During the course of the test, serum glucose (autoanalyzer
method) and insulin (solid phase RIA, Biermann, Bad Nau-
heim, Germany) concentrations were measured at 0, 15, 30, 60,
90, 120, and 180 minutes. The areas under the glucose and
insulin concentration curves during the OGTT were calculated
according to the method of Haffner et al [20]. Impaired glucose
tolerance was defined by use of standards for children proposed
by the National Diabetes Data Group of the National Institutes
of Health: fasting venous plasma glucose concentration <140,
but two-hour glucose level >140 mgldl [21].
Spontaneous GH secretion was assessed by nocturnal GH
concentration profiles in 13 children. The patients were admit-
ted to the hospital in a stable clinical condition for an overnight
stay. Blood was withdrawn from an intravenous cannula from 8
p.m. to 6 a.m. at 20-minute intervals. Stimulated GH secretion
was investigated by a standardized arginine infusion (0.5 g/kg
body wt intravenously over 30 mm). Blood was drawn before
infusion, and 30, 45, 60, 90, and 120 minutes thereafter. Plasma
GH levels were determined centrally by a commercial RIA
(Medgenix, Fleurus, Belgia) with 4.6% intraassay and 8.4%
interassay coefficient of variation.
Insulin-like growth factor I (IGF-I) levels were determined
centrally after acid chromatography [22] by RIA with an anti-
serum provided by Drs. L.E. Underwood and J.J. van Wijk,
and distributed by the National Hormone and Pituitary Program
(Baltimore, Maryland, USA). Serum IGF-II concentrations
were measured in acid ethanol extracts using a specific anti-
serum for the C-peptide domain. Interference of the residual
insulin-like growth factor binding protein (IGFBP) was com-
pletely blocked by addition of excess IGF-I as described [23].
Serum IGFBP-3 levels were measured by a specific RIA. The
acid stable binding subunit of the large GH-dependent binding
protein (IGFBP-3/3) was isolated from human plasma Cohn's
fraction IV and a specific RIA for this protein was developed
which recognizes the large molecular weight complex [24]. No
cross reaction was observed with IGFBP- 1. IGFBP- 1 (identical
to placental protein-l2) and anti-placental protein-12 serum
(donated by Dr. Hans Bohn, Behringwerke, Marburg, Ger-
many) were used for establishing a specific RIA for determina-
tion of IGFBP-l. No cross reaction was observed with
IGFBP-3.
Statistical analyses
Values are expressed as means SD, unless indicated
otherwise. The Wilcoxon signed-rank test was used for within
group changes, with P < 0.05 taken to indicate a significant
difference. Data between treated patients and controls were
compared by Student's t-test, or if normality result failed, by
Mann-Whitney test.
Results
Growth variables
The individual growth data of children, who were prepubertal
at start of GH therapy are presented in Table 3. Seven out of 10
children remained without signs of puberty during the observa-
tion period. Median height velocity increased by more than
three times during the first treatment year and slightly de-
creased during the second treatment year. During the third
treatment year, a more pronounced decrease of height velocity
was noted, but growth rates remained well above the values
obtained before treatment. Interpretation of height velocity
data is complicated in patients 6, 8, and 14 by onset of the
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Table 3. Effect of 1 to 3 years rhGH treatment on height velocity and height velocity SDS related to chronological age in 10 prepubertal
children after renal transplantation
Patient
no.
Height velocity (cmlyear) rhGH therapy Height velocity SDS rhGH therapy Bone age advance years
Baseline 1 year 2 years 3 years Baseline 1 year 2 years 3 years 1st year 2nd year 3rd year
1 5.8 8.6 7.3 6.1 —0.4 3.3 2.7 1.0 1.1 0.8 1.0
2 2.8 7.4 9.1 5.3 —3.8 2.6 5.4 0.3 0.5 0.4 0.6
3 1.9 9.2 7.1 7.7 —4.9 5.1 2.8 2.1 1.8 1.1 0.9
4 4.0 9.4 7.2 5.4 —2.4 5.4 3.0 0.3 0.8 0.9 1.0
5 1.0 7.5 6.8 6.0 —4.9 2.1 1.3 0.0 0.4 0.5 0.6
6 3.9 8.1 7.7 56d —1.0 2.6 1.2 C 1.4 0.9 1.1
7 1.8 4.3 1.8 b —2.1 —0.9 —2.0 b 0.5 0.3 —
8 2.6 9.0 8.7' 37d —1.7 2.2 C C 1.3 1.1 1.0
14 0.3 7.7 55d 49d —0.4 12.1 C C 1.0 0.9 1.2
15 0.7 5.5 a C C C C 0.8 — —
Median 2.2 7.2C 55e —2.1 2.6f 2.7e 0.3 0.9 0.9 1.0
(range) (0.3—5.8) (4.3—9.4) (1.8—9.1) (3.7—7.7) (—0.4—+4.9) (—0.9—+12.1) (—2.0—+5.4) (0—+2.1) (0.4—1.8) (0.3—1.1) (0.6—1.2)
Values are given as median and range.
a Drop out during the 2nd year of therapyb Drop out during the 3rd year of therapy
C Standards to calculate SDS not applicable
d Start of puberty
p < o.os
fp <0.01
pubertal growth spurt during the second and third year, respec-
tively.
The two prepubertal patients with nephropathic cystinosis
(Nos. 7 and 15) responded to rhGH therapy during the first
treatment year; however, in patient No. 7 height velocity
dropped during the second year to the pretreatment level and
the therapy was terminated. Patient No. 15 was excluded from
the study during the second year because of non-compliance.
The growth response (change of height velocity SDS after 1
year of therapy) did not correlate to CCR at start of rhGH
therapy, to methyiprednisolone dose, and to the degree of bone
age retardation. The median bone age advance was in propor-
tion to the increase in chronological age, indicating that bone
maturation was not inadequate. However, a slight acceleration
of bone maturation during the first year, but not later on was
observed in patients No. 3 and No. 6, who both started with a
severe retardation of bone age at baseline and responded well to
rhGH.
Whereas height SDS during the year before onset of therapy
did not change, a significant increased was observed during
rhGH. Median height SDS in the 10 prepubertal children
changed from a baseline of —3.9 (—2.0 to —7.5) SDS to —3.3
(—1.2 to —6.5) SDS after 1 year therapy (P < 0.01). For
prepubertal patients treated over two years (N = 7) the cone-
sponding height SDS data were —3.5 (—2.0 to —4.9) at baseline,
—3.0 (—1.2 to —4.1) after one year, and —2.1 (—0.6 to —4.2)
after two years of therapy. A normal height (>—2 SDS) was
obtained in three out of seven patients after two years and in
three out of five patients after three years of therapy (Fig. 1).
The growth data in pubertal children (Nos. 9 to 13) were fairly
heterogenous and their interpretation was hampered by possi-
ble interference with the pubertal growth spurt. In patient No.
9 with chronic graft rejection, GH therapy was stopped after six
months because parents were concerned of slight deterioration
of graft function. Patient No. 10, who was on high-dose
glucocorticoids, did not respond to rhGH. Patient No. 13
slightly responded during the first treatment year (height veloc-
ity increased from 0 to 2.7 cmlyear), but stopped therapy
thereafter. Patients No. 11 and 12 responded well to rhGH
(height velocity increased from 5.5 to 8.5 and from 2.4 to 7.7
cm/year in the first treatment year). Their cumulative height
gain over three years of therapy was 24.5 cm and 16.3 cm,
respectively.
As expected, baseline height SDS in rhGH treated patients
was significant lower than in "controls", but growth before
rhGH treatment, expressed as height SDS/year, did not differ
between the groups (Table 2). During the first two treatment
years height SDS/year was markedly higher in rhGH treated
patients despite lower GFR and higher corticosteroid treatment
compared to "controls," the difference in the third year was
less evident.
MAC slightly increased during the first treatment year [base-
line 19.1 (15.8 to 25.0) cm; 12 months 20.1 (16.8 to 23.5), P <
0.01], similarly MAMC [baseline 16.7 (14.7 to 19.9) cm; 12
months 18.2 (16.4 to 21.2), P < 0.01], whereas TSF thickness
0
a,
—2
0
C/)
C)
Fig. 1. Height SDS related to chronological age in JO prepubertal
children before and during I to 3 years of rhGH therapy. Only
prepubertal height SDS data are given. The lower limit of the normal
range (—2 SDS) is marked by the dotted line. Numbers indicate
individual patients.
1 year Baseline 1 year 2 years 3 years rhGH
w
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Table 4. Inulin clearances (C1,,) (mI/min/1.73 m2) during the first year
of rhGH therapy in 10 children with renal allografts
2
* *
**
**
**
0
Patient
no.
Cm
Change of
C1,, per yearBaseline
6 weeks of
therapy
12 months
of therapy
ia 60.0 55.0 64.6 +4.6
3 110.1 94.8 102.2 —7.94 34.5 35.8 33.7 —0.8
5 35.9 35.7 29.2 —6.7
6 117.9 107.2 100.0 —17.97 25.1 23.5 18.5 —6.6
8 96.5 106.0 90.0 —6.5
l1 89.4 107.4 84.6 —4.8
i2 58.6 52.6 31.8 —26.8
isa 22.7 23.4 19.5 —3.2
Median 59.3 53.8 49.2" —6.6
(range) (22.7—117.9) (23.4—107.2) (18.5—102.2) (—26.8—+4.6)
—2
0 1.5 3 6 9 12
Time, months
Fig. 2. IGF-I, IGF-11 (-D- -), IGFBP-3 (- * -) serum concentration and
JGF-bioactivity (_L_) expressed as standard deviation score (SDS) in 10
children with renal transplants before and during 12 months of rhGH
therapy. Values are given as mean SEM. *P < 0.05, < 0.005 vs.
baseline; rhGH treatment increased IGF-I serum concentration and
normalized IGF bioactivity.
decreased already during the first three months of therapy
[baseline 6.1 mm (3.4 to 18.0); 3 months 4.9 (3.2 to 12.2), P <
0.01; 12 months 5.4 (4.0 to 13.0), P < 0.05]. This indicates a
rapid decrease of adipose tissue and a slower increase in mucle
mass. The weight for height ratio was 107% (99 to 125) at
baseline and did not change during the treatment course.
Endocrine evaluations
In the children tested for GH secretion GH deficiency was
excluded by GH plasma levels exceeding 10 ng/mI in either the
GH night profile or the stimulation test with arginine in all
except patient No. 8 (Table 1). A high interindividual variability
of GH plasma levels in both tests was observed.
The effect of rhGH on longitudinal growth was accompanied
by remarkable changes in the serum concentrations of the
GH-dependent IGF-I and IGFBP-3 (Fig. 2). To account for age
dependence values were given as SDS. At baseline, immuno-
reactive IGF-I serum concentrations were in the normal range,
but IGF-bioactivity was reduced by 2 SD. IGFBP-3 levels were
clearly elevated at baseline. During GH treatment IGF-I levels
increased rapidly by more than 4 SD and remained elevated
during the first treatment year. In contrast, basal elevated
IGFBP-3 levels showed only a slight and transiently significant
increase. The increase of IGF-I was paralleled by a normaliza-
tion of the IGF-bioactivity. IGF-II serum levels at baseline
were in the normal range and did not change during 12 months
treatment (Fig. 2). IGFBP-1 values were markedly increased at
baseline (110.4 63.9ng/ml corresponding to 13.8 7.7 SDS)
and did not change during the treatment course (3 months of
therapy: 94.4 51.1 ng/ml, 6 months: 100.4 45.2 nglml).
—1 year Baseline 1 year 2 years 3 years rhGH
a Patients with chronic graft rejection in renal histology
b P < 0.05 vs. baseline
120
100
N 80
60
E 40
0o 20
0
Fig. 3. Calculated creatinine clearances (Ccr) in 13 children with renal
transplants in the year before treatment and during Ito 3 years of rhGH
therapy. The median C. of 10 children treated over 3 years is indicated
by (8-). The fall of Ce,. per year before and during rhGH therapy was not
statistically different.
Renal function
GFR as measured by repeated C1,, in 10 children remained
stable during the first year of therapy in all patients but one (No.
12), who had histologically proven chronic graft rejection. The
median loss of Cth was 6.6 ml/min/1.73 m2 per year (Table 4).
The loss of GFR as calculated by CCR during one to three years
of rhGH therapy was not significantly different from that in the
year before treatment (Figs. 3 and 4). The median change of
GFR/year in patients treated with rhGH for three years (N =
10) was 2 ml/min/1.73 m2 (range —19 to 5) before treatment, 2
(—20 to 12) during the first, —7 (—15 to 15) during the second,
and —3 (—16 to 3) during the third year of treatment (NS).
Baseline GFR in rhGH treated patients was significantly lower
(P < 0.05) than in "controls," but the decline of graft function
during the treatment period was not significantly different
between the two groups; it rather tended to be higher in the
"control" group (Fig. 4). The median loss of GFR in the
controls followed for three years (N = 16) was —7 (—43 to 8) in
the first, —10 (—30 to 4) in the second, and —7 (—32 to 37) in the
third year of observation.
In all 17 patients with a cumulative observation period of 364
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Table 5. Metabolic and renal parameters before and during rhGH therapy
Parameter
Baseline
(N = 15)
6 Months of
therapy(N = 15)
1 Year of
therapy(N = 13)
2 Years of
therapy(N = 11)
3 Years of
therapy(N = 10)
Fasting serum glucose mg/dl 80 (54-104) 9P (54—117) 90 (76—118) 82 (61—90) 83 (66—100)
Glucose, area OGTT mg/dl 222 (178—359) 214 (202—410) 236 (159—310) 234 (173—314) 227 (209—280)
Fasting serum insulin mU/liter 8 (3—25)(N=7) 15.1 (3.0—55.0)(N=7) 26 (10—72)(N=7)
25 (3—97)(N=7) 41 (18—139)(N=4)0
Insulin, area OGTT mU/liter 84 (58—157)(N=7) 137 (57—212)(N=7) 159a (134—225)(N=7)
l55 (78—245)(N=7) 218 (168—540)(N=4)
HbAIC (normal range 4.3 0.5%) 4.8 (4.0—5.8) 4.9 (4.3—5.0) 4.5 (4.0—4.8) 4.5 (3.9—5.0) 4.5 (3.8—5.0)
Serum cholesterol mg/dl 249 (188-325) 227 (171—288) 249 (156—365) 232 (152—304) 231(180-274)
Serum triglycerides mgldl
Alkaline phophatase U/liter
204 (61—550)
228 (81—451)
209 (74-347)
397" (115—1068)
176 (26—406)
414" (220—703)
174 (89—337)
402 (130—635)
207 (59—356)
375 (144—570)
Urinary calcium/creatinine ratio 0.12 (0.03—0.25) 0.08 (0.02—0.14) 0.08 (0.03—0.15) 0.07 (0.03—0.01) 0.05 (0.03—0.08)
mg/mg
Urinary protein excretion 0.11 (0.01—1.5) 0.12 (0.03—1.78) 0.10 (0.02—2.0) 0.36 (0.04—1.46) 0.21 (0.09—0.7)
g/m2/day
a p < 0.05 vs. baseline, b p < 0.001 vs. baseline
months three acute rejection episodes (defined by clinical
and/or histological means) occurred, equivalent to 0.10 epi-
sodes per patient and year. These episodes occurred 6 weeks,
14 months, and 20 months after initiation of rhGH therapy. In
the "control" group not treated with rhGH eight acute rejection
episodes were documented over a cumulative observation
period of 780 months, equivalent to 0.12 episodes per patient
and year.
Metabolic parameters
Fasting serum glucose concentrations increased slightly, but
significantly after 6 and 12 months of therapy, the values after
two and three years of therapy being not significantly different
from baseline (Table 5). Integrated serum glucose concentration
during the OGTF did not change during the observation period.
One patient (No. 15) out of three with nephropathic cystinosis
had a pathological OGTT at baseline, which did not deteriorate
during the treatment course. Glycosylated hemoglobin concen-
trations remained stable (Table 5). Insulin secretion, however,
was significantly elevated (Table 5). Fasting serum insulin
levels increased during the first and second year of therapy, a
further rise was noted in each of the four children tested after
three years. A similar increase was observed when the inte-
grated serum insulin concentration during the OGTT was
calculated. Serum alkaline phosphatase activity transiently
increased after 6 and 12 months of therapy, but decreased
during the second and third year. There was no significant
change in serum cholesterol, serum triglycerides, urinary cal-
cium excretion, urinary protein excretion (Table 5), intact PTH,
inorganic phosphate, thyroid hormones, haemotological param-
eters and blood pressure (data not shown).
Discussion
The present study is the first that has investigated the
efficacy, endocrine mechanism, and safety of rhGH treatment
over a period of up to three years in short children after renal
transplantation. It demonstrates that rhGH therapy in a dose of
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Fig. 4. Mean (± 5EM) glomerular filtration
rate (GFR) as estimated by creatinine
clearances according to Schwartz [19] in
retrospective "controls" (• •; N = 22, 3
- years N = 16) and in children before and
during 2 years (A) (•----•; N = 11) and 3
years (B) (N = 10) of rhGH treatment. The
- GFR at start of rhGH treatment wasI I I
—1 year start 1 year 2 years 3 years significantly (P < 0.05) higher in "controls,"
and the fall of GFR/year was not statistically
rhGH treatment different between "controls" and rhGHtreated patients.
—1 year start 1 year 2 years
rhGH treatment
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30 IU/m2/week persistently improves growth in short, slowly
growing prepubertal children after renal transplantation without
serious side effects, in particular without induction of acute
rejection episodes. In contrast, the effect of rhGH on longitu-
dinal growth in pubertal children was less consistent and
difficult to differentiate from the endogenous pubertal growth
spurt.
The mechanisms for impairment of growth after renal trans-
plantation are not fully understood. Impaired graft function and
immunosuppressive treatment, by glucocorticosteroids, seem
to be the major contributing factors [2]. However, some grafted
patients with good renal function and on low-dose steroid
treatment, such as patients No. 3 and 6 in our study, do also not
grow sufficiently. In these patients, growth retardation may be
considered as a consequence of glucocorticoid-induced GH
hyposecretion [4]. However, only one of the patients in the
present study fulfilled the criteria of growth hormone deficiency
evaluated by growth hormone night profiles and provocation
tests with arginine. This may be explained by the relatively low
glucocorticoid doses used in our patients. Immunoreactive
IGF-I serum levels in our study were normal, whereas IGF-
bioactivity was clearly reduced (Fig. 2). These data are in
accordance with other findings reporting normal immunoreac-
tive IGF-I values and decreased somatomedin bioactivity in
poorly growing transplanted children [25, 26]. Data about
IGFBP's have not been reported before. In our study, the
IGFBP-l and -3 serum levels were increased markedly. This
situation is reminiscent to the alterations of the IGF binding
proteins observed in uremic children with terminal or pretermi-
nal chronic renal failure [27, 28]. It has been shown by previous
work from our group that IGFBP-3 fragments, which are
normally cleared from the circulation by renal filtration, accu-
mulate in uremia and act as IGF inhibitors by forming low
molecular weight complexes with IGF-I [27]. In addition,
glucocorticoids therapy may have contributed to the decreased
IGF bioactivity, similar to patients with untreated Cushing's
syndrome and normal renal function, who have a depressed
IGF activity, possibly as a consequence of circulating IGF
inhibitors [26]. Also the secretion of IGF-I might be altered by
glucocorticoids, which have been shown to inhibit in vitro the
production of IGF-I mRNA in liver [29] as well as in bone [30].
Taking these data together, the inhibition of IGF-I and in-
creased IGF binding capacity seems to be pivotal to the
inhibition of body growth after renal transplantation. RhGH
therapy in our study improved the ratio between the serum
concentration of IGF-I and IGFBP-3, thereby normalising the
IGF-bioactivity in the growth cartilage bioassay (Fig. 2). This is
explained by the fact that GH stimulates IGF-I secretion in a
linear, but IGFBP-3 secretion in a logarithmic fashion (W.F.
Blum, unpublished observation). The resulting higher availabil-
ity of free IGF-I is a possible explanation for the growth
promoting effect of rhGH in the present study. These data also
provide a rationale for rhGH treatment in those children after
renal transplantation, who secrete normal amounts of GH, but
have decreased biologically available IGF's.
Interestingly, the effect of rhGH was not correlated to graft
function nor to methylprednisolone dosage. This indicates that
also children with an unfavorable height prognosis as a conse-
quence of chronic graft rejection and glucocorticoid treatment
can profit from this new treatment modality. This is in contrast
to animal studies, which showed a clear cut dependence of the
growth response by rhGH from the glucocorticoid dose used
[7]. This discrepancy might be explained by the relatively low
dosage of methylprednisolone in the present study and the
relatively high dosage of rhGH.
Since growth inhibition in transplanted children is partially
due to treatment with glucocorticoids, reduction or even dis-
continuation of steroids has been discussed as a therapeutic
approach to improve longitudinal growth in these children.
During alternate-day glucocorticoid treatment growth improves
in some, but not all children with renal transplants, in particular
in those with normal graft function [31], but the effect is
heterogenous and in general less pronounced than the growth
stimulation by rhGH observed in the present study. In a
controlled study, which compared alternate day prednisone
therapy to daily treatment in 16 prepubertal children with renal
transplants, a mean z height SDS of +0.27 was observed
compared to a SDS of —0.15 on daily steroid treatment [32].
Only a few centers have studied the effect of steroid withdrawal
on growth and graft function [33, 34]. In 12 children with a
serum creatinine below 2.0 mgldl, a mean z SDS of 0.8 0.3 in
the first year, and 0.3 0.2 in the second year after transplan-
tation was observed, indicating that at least in children with
only slightly reduced graft function, catch-up growth does
occur after steroid withdrawal [331. However, this regimen
increases the risk of graft rejection with a reported incidence of
50% to 60% [35] and requires the administration of higher doses
of cyclosporine, which increases the risk of cyclosporine neph-
rotoxocity. The question, whether withdrawal of glucocorti-
coids or treatment with rhGH is superior in respect to growth
and preservation of graft function, can only be solved by a
randomized controlled study.
A major concern in the OH treatment of short children after
renal transplantation regards the induction of acute or the
aggravation of chronic rejection crises. There is experimental
and clinical evidence that the immunosuppressive effects of
glucocorticoids can be counteracted by exogenous GH. In
mice, methylprednisolone-induced weight reduction of the thy-
mus and spleen, as well as a decrease in the number of T
lymphocytes can be prevented by concomitant OH supply [36].
In healthy subjects, GH application increases the tumor-cyto-
toxic activity of natural killer cells [37]. In the present study,
the frequency of acute rejection crises was not higher than in
the non-rhGH treated control group; it was also similar to the
incidence of acute rejection crises in two other studies, which
was reported as 0.14 [8] and 0.06 episodes per patient and year
[9]. This indicates that there is no substantial effect of rhGH
treatment on the induction of acute rejection episodes.
An effect of OH therapy on chronic graft rejection is more
difficult to assess because of the variability and unpredictability
of the disease. The measurement of OFR by C1, demonstrated
only a slight median loss of 6.6 mllmin/l .73 m2 per year during
GH therapy. In single children with chronic graft rejection
(such as patient No. 12) a more pronounced decline of graft
function during the first year of treatment was observed, but a
similar decline in GFR of up to 30 mllmin/1 .73 m2 was also
noticed in individual cases of the control group. Two arguments
indicate that rhGH does not substantially deteriorate renal
function, similar as in children with preterminal renal failure
[38]: (i) the loss of GFR as estimated by Cr did not change
206 TOnshoffet a!: rhGH in short children with renal a!lografts
significantly during rhGH therapy compared to the year before
treatment (Fig. 3); and (ii) the loss of GFR during three years of
rhGH treatment was not significantly higher than that of retro-
spective "controls" (Fig. 4). In view of the limited precision of
GFR measurements by calculated creatinine clearances, a slight
deterioration of graft function in rhGH treated patients cannot
be excluded by our study. This would require a prospective
randomized placebo controlled study over three and more years
including measurement of GFR with inulin clearances, which
however, would be difficult, if not impossible to perform.
The main metabolic change induced by exogenous GH in this
study was an increase of insulin secretion, which continued to
progress during the three years of treatment, whereas glucose
tolerance as measured by OGTT and determination of glycosi-
lated hemoglobin concentrations did not change in any of the
studied children. Hyperinsulinemia and relative insulin resis-
tance is a well known general effect of exogenous GH admin-
istration [39]. Especially in children with renal allografts this
metabolic change may be potentially harmful, since a pre-
existing relative insulin resistance by the combined effect of
pharmacological doses of glucocorticoids [40] and uremia [41]
seems to be further aggravated by rhGH therapy. The long-term
consequences of increased insulin secretion are uncertain, but
hyperinsulinemia per se has been implicated as a direct caus-
ative factor in the pathogenesis of atherosclerosis [42]. In
addition, chronic stimulation of the pancreatic /3-cells by GH
treatment may lead to exhaustion of insulin secretory capacity
over time as observed in patients with acromegaly [43]. How-
ever, at least in short normal children treated with a very high
dose of GH (55 IU/m2/week), the hyperinsulinemia and relative
insulin resistance observed after two years of rhGH adminis-
tration was reversible, after GH therapy was discontinued [44].
Our results are in contrast to the study of van Dop et al [45],
who did not find increased insulin secretion during OGTT in
eight transplanted children treated with rhGH for one year. This
discrepancy may be due to the lower rhGH dose in the previous
study and/or to the different dosis regimen (daily injections in
our study vs. 3, 6, or 7 injections per week in van Dop's study).
In conclusion, the present study documents a marked growth
promoting effect of rhGH in short children after renal transplan-
tation without serious side effects. Further observation until
adult height is, however, essential, before a definitive judgment
of this new treatment modality can be made, since the effect of
rhGH on pubertal development in children with renal trans-
plants is not known. An improvement of height resulting from
rhGH treatment in the prepubertal period could theoretically be
lost by early onset and shortened duration of puberty [46]. The
changes in body composition observed during the first treat-
ment year indicate that not only the growth depressing effects of
glucocorticoids, but also their effects on adipose tissue forma-
tion can be counteracted by concomitant rhGH therapy. Con-
sidering the potentially harmful consequences of rhGH therapy
on glucose metabolism, a regular monitoring of safety parame-
ters in controlled clinical studies is mandatory.
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